Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 5:32 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 17,088 matching trials from the live ClinicalTrials.gov search.
Filters: Philadelphia, Pennsylvania Clear all
Completed Phase 3 Interventional Results available

Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.

NCT01197534
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
fostamatinib, placebo, fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
913 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
57
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Nov 1, 2026, 5:32 AM EST
Completed Phase 2 Interventional

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

NCT00053209
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
gemcitabine hydrochloride, pemetrexed disodium
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
121
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 88 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Nov 1, 2026, 5:32 AM EST
Completed Phase 2 Interventional Results available

Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer

NCT00003298
View directory record Official record
Conditions
Gastric Cancer
Interventions
cisplatin, fluorouracil, leucovorin calcium, paclitaxel, surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2011
U.S. locations
30
States / cities
Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Nov 1, 2026, 5:32 AM EST
Completed Phase 3 Interventional Results available

A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

NCT05096221
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
delandistrogene moxeparvovec, placebo
Genetic
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
4 Years to 7 Years · Male only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
23
States / cities
Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Nov 1, 2026, 5:32 AM EST
Active, not recruiting Phase 2 Interventional

TReatment for ImmUne Mediated PathopHysiology

NCT04862221
View directory record Official record
Conditions
Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions
High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
1 Year to 18 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 1, 2026, 5:32 AM EST
Completed Not applicable Interventional

The Effect of a Scratch Off Prompt on Health Engagement

NCT01401621
View directory record Official record
Conditions
Blood Pressure Check (Hypertension Screening), Cholesterol Test (Lipid Disorder Screening)
Interventions
Scratchoff Prompt: Name of Test, Scratchoff Prompt: Call to Action, Control
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
84,953 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Nov 1, 2026, 5:32 AM EST
Terminated Not applicable Interventional Results available

Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

NCT02132884
View directory record Official record
Conditions
Malignant Pericardial Effusion, Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cytology specimen collection procedure, therapeutic procedure, targeted therapy, laboratory biomarker analysis
Other · Procedure · Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2019 · Synced Nov 1, 2026, 5:32 AM EST
Completed Phase 2 Interventional Results available

Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK

NCT02227147
View directory record Official record
Conditions
Neurotrophic Keratitis
Interventions
rhNGF 20µg/ml, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Loma Linda, California • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Nov 1, 2026, 5:32 AM EST
Completed Phase 1 Interventional

A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

NCT01493726
View directory record Official record
Conditions
Schizophrenia
Interventions
ALKS 9072, Low dose, ALKS 9072, Med dose, ALKS 9072, High dose, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Atlanta, Georgia • Hoffman Estates, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Nov 1, 2026, 5:32 AM EST
Completed Not applicable Interventional Results available

Shifting Perspectives: Enhancing Outcomes in Anorexia Nervosa With CRT

NCT03928028
View directory record Official record
Conditions
Anorexia Nervosa
Interventions
Cognitive Remediation Therapy, Family Based Treatment
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
12 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Nov 1, 2026, 5:32 AM EST
Completed Phase 2 Interventional Results available

Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery

NCT01164228
View directory record Official record
Conditions
Kidney Cancer
Interventions
Gemcitabine, Sunitinib
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
99
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Stanford, California + 77 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Nov 1, 2026, 5:32 AM EST
Recruiting No phase listed Observational

Nephrotic Syndrome Study Network

NCT01209000
View directory record Official record
Conditions
Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
Interventions
Kidney Biopsy
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
Up to 80 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
39
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Nov 1, 2026, 5:32 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Assessing Fertility Potential in Female Cancer Survivors

NCT01143844
View directory record Official record
Conditions
Effects of Chemotherapy
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
11 Years to 50 Years · Female only
Enrollment
391 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2020
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Radnor, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Nov 1, 2026, 5:32 AM EST
Completed No phase listed Observational

Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B

NCT00195221
View directory record Official record
Conditions
Hemophilia B, Allergic Reactions
Interventions
Not listed
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
Not listed
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
15
States / cities
Phoenix, Arizona • Orange, California • Atlanta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Nov 1, 2026, 5:32 AM EST
Active, not recruiting Phase 2 Interventional

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

NCT07011706
View directory record Official record
Conditions
Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema
Interventions
ATI-045, Placebo
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
53
States / cities
Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 1, 2026, 5:32 AM EST
Completed Phase 3 Interventional Results available

A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

NCT03447249
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-659/TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
48
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 44 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2020 · Synced Nov 1, 2026, 5:32 AM EST
Recruiting Phase 1 Interventional

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

NCT07408258
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
ONC-783
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
New York, New York • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 1, 2026, 5:32 AM EST
Completed Not applicable Interventional Results available

Zenith TX2® Post-market Approval Study

NCT00813358
View directory record Official record
Conditions
Descending Thoracic Aortic Aneurysm
Interventions
Zenith TX2® TAA Endovascular Graft
Device
Lead sponsor
Cook Research Incorporated
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
24
States / cities
San Francisco, California • Aurora, Colorado • Gainesville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Nov 1, 2026, 5:32 AM EST
Completed Phase 3 Interventional

Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes

NCT00399711
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
repaglinide and metformin combination tablet, rosiglitazone and metformin combination tablet
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
102
States / cities
Vestavia Hills, Alabama • Glendale, Arizona • Mesa, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Nov 1, 2026, 5:32 AM EST
Not listed No phase listed Observational

Colonic Transit Time Validation Study

NCT00857363
View directory record Official record
Conditions
Constipation
Interventions
Not listed
Lead sponsor
The SmartPill Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Tucson, Arizona • Los Angeles, California • Iowa City, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Nov 1, 2026, 5:32 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

NCT04334148
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Placebo oral tablet
Drug
Lead sponsor
Adrian Hernandez
Other
Eligibility
18 Years and older
Enrollment
1,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
34
States / cities
Aurora, Colorado • Gainesville, Florida • Jacksonville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Nov 1, 2026, 5:32 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

NCT00288119
View directory record Official record
Conditions
Barrett's Esophagus, Esophageal Neoplasm
Interventions
Balloon Capsule Device, Endoscopy
Device · Procedure
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2028
U.S. locations
10
States / cities
Baltimore, Maryland • Rochester, Minnesota • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Nov 1, 2026, 5:32 AM EST
Not listed Phase 1 Interventional

Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin

NCT00652119
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Paclitaxel, Carboplatin, Avastin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Nov 1, 2026, 5:32 AM EST
Suspended Not applicable Interventional

A Personalized Prehabilitation Intervention In Elective Joint Replacement Surgery

NCT03601728
View directory record Official record
Conditions
Arthropathy of Knee Joint, Arthropathy of Hip Joint
Interventions
personalized prehabilitation
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
55 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Nov 1, 2026, 5:32 AM EST